| ||||||||||||||
|
|
|||||||||||||








*Department of Anesthesiology and
Division of Pulmonology, Childrens Hospital of Pittsburgh; and the Departments of
Anesthesiology and
Pediatrics, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania
Address correspondence and reprint requests to Gavin F. Fine, MB, BCh, Childrens Hospital of Pittsburgh, Department of Anesthesiology, 3705 Fifth Ave., Pittsburgh, PA 15213. Address e-mail to finegf{at}anes.upmc.edu
The administration of rapacuronium increases the risk of severe bronchospasm. There have been no studies of pulmonary function directly demonstrating airway constriction with rapacuronium in children. In this study, 10 ASA physical status I or II patients (aged 26 yr) were randomly divided into 2 equal groups, receiving either rapacuronium or mivacurium. Anesthesia was induced with sevoflurane and maintained with remifentanil (0.20.3 µg · kg-1 · min-1) and propofol (200250 µg · kg-1 · min-1) infusions. We performed three sets of pulmonary function tests: baseline, after the administration of muscle relaxant, and after the administration of a ß2 agonist. In both groups, there were no changes in static respiratory compliance. The increase in total respiratory system resistance after the administration of rapacuronium did not reach statistical significance (214.4% ± 122.65% of baseline, P
0.1), whereas maximal expiratory flow at 10% of forced vital capacity (MEF)10 and MEFfunctional residual capacity on partial flow-volume curves by the forced deflation technique decreased markedly (53.4% ± 18.49%, P < 0.01 and 41.3% ± 27.42%, P < 0.001, respectively). With the administration of mivacurium, no changes were observed in respiratory system resistance (109.5% ± 30.28%). MEF10 decreased slightly (77.0% ± 9.03%, P < 0.005) whereas MEFFRC did not (81.2% ± 29.85%, not significant). After the administration of a ß2 agonist, all measurements returned to baseline. Thus, the administration of rapacuronium consistently results in lower airway obstruction with minimal changes in static respiratory compliance when compared with mivacurium.
IMPLICATIONS: Pulmonary function tests in the present study showed that rapacuronium consistently causes severe bronchoconstriction, confirming clinical case reports of bronchospasm. The bronchoconstriction is reversible with albuterol. Mivacurium also causes very mild subclinical bronchoconstriction.
This article has been cited by other articles:
![]() |
F. Petak, Z. Hantos, A. Adamicza, H. Gality, and W. Habre Development of bronchoconstriction after administration of muscle relaxants in rabbits with normal or hyperreactive airways. Anesth. Analg., July 1, 2006; 103(1): 103 - 109. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. J. Bishop, J. T. O'Donnell, and J. R. Salemi Mivacurium and Bronchospasm Anesth. Analg., August 1, 2003; 97(2): 484 - 485. [Abstract] [Full Text] [PDF] |
||||
|